Therapixel Announces Launch Of Prospective.Study on The Utility of Artificial intelligence (AlAs Part Of second Reading Breast CancerScreening Mammograms
来源:   时间:2025-08-02

Paris and Nice, 0ctober 19th, 2022 - Therapixel, a French company specialized in the detection of breastcancer using artificial intelligence (Al), announces the start of a prospective clinical study to evaluate thecontribution of Al in the second reading of screening mammograms.

Breast cancer can be cured in 90% of cases, if caught in time, which is based on the earliest possibledetection. In the French breast cancer screening program, a first radiologist at a licensed office performsand reads the mammogram, if no abnormalities are found, the images are sent to the regional screeningstructure (CRCDC) for proofreading by a second radiologist, qualified for this second reading. The shortageof expert radiologists for this second reading is increasing, and the process is still very manual: the imagesare printed on films and sent to the management structure by courier, which lengthens the patient's time tobe informed of their screening results. The opportunity is to accelerate the processing of the result throughthe digitization of the process and the addition of an Al tool to automatically negate a part of the cases, toleave to the expert radiologist only the contentious cases, that is to say when the Al and the first reader donot agree.

INEW00

This use case is expected to bring many benefits: the same quality of care, a faster final report for patientsand a lower cost.

The study is prospective in real life in the PACA region, in France, and involves eight radiology offices .Cabinet de Radiologie du Cabot (Marseille), Centre de radiologie Les Défensions, (Aubagne), the centres ofVAR lmagerie Médicale : Centre Le France (Draguignan), Centre de la Gare (Saint-Raphael), Clinique desLauriers (Fréjus), Centre d"lmagerie Médicale Epsilon (Saint-Raphaěl), Ce'tre d"lmagerie Médicale Le ClippeiTassigny), Ce'tre d'lmagerie Médicale Mistral (Sainte-Maxime), CRCDC Sud PACA and two industrialists(maging Solutions for Scanning and Therapixel for Al. The study will look at 5,000 women participating inorganized screening. The Al scenario provides an opinion in parallel with the traditional reading, so that therecan be no misses for the patient. This study will aim to show that for some Al scores, with a very lowprobability of malignancy, an automatic second reading can be considered without risk of missing cancerThus, the second-reading radiologists will focus on the most complicated cases.

Dr Seradour, President of the CRcDc Sud PACA says: "This study, which we are launching in partnership withCRCDC Sud Paca-Solutions lmaging-Therapixel, is the first French experiment in the framework of organizedscreening, on the interest of Al in 2nd reading. t will allow us to assess the role of Al in reducing the number of second reads in cases ofneqative Al results."

Patrice Heid, Director of the CRCDC Sud PACA adds: "lt is also, in parallel with this very important researchproject for the future of the second reading, a first PACA test of dematerialization ofmammography images.There will be no change in the process of second reading, but the addition of a completely digitized stream inparallel with the current film circuit., This is crucial to ensure the quality of our program and patient safety. Thisproject wil be deployed on two CRCDc Sud PACA antennae, and will involve 8 of our radiology centers and all ofNEVour second readers.

Thierry Boisson, Chief Executive Officer of Solutions lmaging, says: "This study is part of the process ofinnovation and improvement of our Gédéon software (dematerialization of the L2). Explore the economicpotential of Al in our solution and achieve a performance that will combine improved prevention, diagnosticaccuracy, cost control and address human resources issues.

Thomas Bertinotti, Chief Product Director at Therapixel, adds: "Evaluating a second-reading scenario thatcombines mammography dematerialization and artificial intelligence is a major step forward for organizedbreast cancer screening. ln addition to solving a real problem using innovative technologies, this type of useoffers new evolutionary perspectives such as the introduction of tomosynthesis in organized screening.

About Therapixel

Therapixel is a French company specialized in the design and commercialization of Alpowered medicalimaging software, with the goal of delivering pertinent information at the right time to healthcareprofessionals. Winner of the Digital Mammography DREAM Challenge in 2017, the global competition onbreast cancer detection with Al, Therapixel has developed MammoScreen@, a software that helps with theinterpretation of screening 2D and 3D mammograms. With MammoScreen@, even experienced radiologistscan improve their performance, feel more confident in their judgment, and reassure women quicker. Findmore at www.mammoscreen.com

Contact:

Neliya Tumbeva

media@therapixel.com